Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression, and guide treatment decisions across medical specialties where critical genetic insights can significantly improve patient care and lower healthcare costs. Fast Company named Myriad among the World’s Most Innovative Companies for 2022.
Paul J. Diaz, was named president, chief executive officer and member of the Myriad Genetics board of directors on August 13, 2020. Paul was most recently a partner at Cressey & Company (2016-2020), a private investment firm headquartered in Chicago, Illinois, which currently manages over $3.0 billion in committed capital. Cressey & Company is a healthcare focused middle-market private equity firm with over 30 years of success investing in and helping to build high quality healthcare businesses. Paul is the former president and chief executive officer and vice chairman of Kindred Healthcare, Inc. (NYSE:KND) (2002-2016) a Fortune 500 Company and one of the largest providers of healthcare services in the United States. At the time, Kindred had revenues of $7.2 billion, rehabilitation hospitals, sub-acute units, home health and hospice agencies and contract rehabilitation locations. For six years in a row, during his tenure as CEO, Kindred was ranked one of the Most Admired healthcare companies in the U.S. by Fortune magazine. Paul currently serves on the board of directors of DaVita (NYSE: DVA), the board of trustees of Johns Hopkins Medicine (where he serves as chair of Johns Hopkins Healthcare), and the board of visitors of the Georgetown University Law Center. He was formerly on the board of directors of PharMerica Corporation (NYSE: PMC), and previously served on the board of the federation of American Hospitals, and the Bloomberg School of Public Health at John Hopkins University. While chief executive officer of Kindred, Paul was a member of the Business Roundtable and the Wall Street Journal CEO Council. Modern Healthcare magazine named Paul one of the 100 Most Influential People in Healthcare and named him one of the top 25 Minority Executives in Healthcare for numerous years. In addition, Hispanic magazine named Paul one of the 25 Best Latinos in business in multiple years. Paul earned a bachelor’s degree in Finance and Accounting from American University’s Kogod School of Business and a law degree from Georgetown University Law Center in Washington, D.C.
Maggie Ancona, senior vice president, Transformation and Chief of Staff to the CEO, joined Myriad Genetics in January 2021. Previously, she led Global Transformation and Program Management at Hewlett Packard (HP) and Dell Technologies where she oversaw business transformation strategy, executed large-scale programs and cost management efforts, while retooling digital infrastructure for the future. Mrs. Ancona received a bachelor’s degree in English from the University of San Francisco.
Kevin R. Haas, chief technology officer, joined Myriad Genetics in May 2013. Previously, he was vice president of Bioinformatics. Dr. Haas also serves on the Board of Directors and is vice president for USA Triathlon, the non-profit national governing body for the sport. Dr. Haas received a B.S. from University of Wisconsin-Madison and a Ph.D. in Chemical Engineering from University of California-Berkeley, where he worked on molecular simulation and machine learning to study protein dynamics from single molecule fluoresce. He has co-authored 16 peer reviewed publications and eight patent applications.
Jayne B. Hart joined Myriad Genetics in May 2011 as chief people officer. She has more than twenty years of professional experience in the human resources field. Prior to joining Myriad, Ms. Hart served as vice president of human resources at LANDesk Software, a global software company. Before that, she was vice president of human resources for 360networks, a wholesale telecommunications company, and at AT&T Wireless, a global telecommunications company, where she began her career.
Nicole Lambert is chief operating officer of Myriad Genetics, promoted in December 2021. She joined Myriad Genetics in June 2001 and continues to serve as Group President of Myriad Oncology, Women’s Health and International businesses. Previously, she served as general manager for the Oncology and Urology business units and vice president of Dermatology. Prior to joining Myriad, she was a genetic counselor at LabCorp. Mrs. Lambert received her bachelor’s degree in Biology and Sociology from Boston College and earned her master’s in genetic counseling from Mt. Sinai School of Medicine at New York University. She currently serves a member of the Board of Directors of Arcus Biosciences.
Dale Muzzey, Ph.D., is chief scientific officer of Myriad Genetics. He joined the company in April 2014. Previously, he was senior vice president of R&D. Before joining Myriad, he was a postdoctoral scholar at University of California, San Francisco, with a fellowship from the Damon Runyon Cancer Research Foundation. Dr. Muzzey received a B.A. with honors in Biochemical Sciences from Harvard University and a Ph.D. in Biophysics from Harvard University. His thesis research applied signal-processing techniques to cellular signal-transduction cascades to better understand how response dynamics revealed insight into network architecture.
Bryan Riggsbee, chief financial officer, joined Myriad Genetics in October 2014. He previously served 10 years with Laboratory Corporation of America (LabCorp) where his most recent position was as senior vice president of Corporate Finance with responsibility for the financial planning and analysis and treasury functions. Prior to LabCorp, Mr. Riggsbee served in various finance roles with General Electric and began his career in the audit division of KPMG. He received a B.A. degree in Accounting from North Carolina State University, a B.A. degree in Political Science from the University of North Carolina at Chapel Hill and an M.B.A. from Northwestern University. Mr. Riggsbee is a Certified Public Accountant licensed in the State of North Carolina.
Mark Verratti was promoted to chief commercial officer of Myriad Genetics in April 2022, responsible for accelerating the enterprise growth team to enhance commercial and marketing capabilities, gain new customer insights, and enhance demand generation. In addition to his expanded enterprise role, he also continues to oversee Myriad’s Mental Health business, including the GeneSight® pharmacogenomics test. Mr. Verratti has more than 20 years of experience leading large commercial organizations in the pharmaceutical and medical device industries. He has held senior and general management positions with Cyberonics/LivaNova leading teams in over 70 countries. He received a B.S. in Life Sciences with a minor in Physiology from The Pennsylvania State University.
Pamela Wong, chief legal officer, joined Myriad Genetics in October 2021. She leads the company’s legal function, including support and counsel for all legal affairs, intellectual property, patent protection, mergers and acquisitions, litigation, regulatory and quality assurance, compliance, and government affairs. She previously served 14 years at Quest Diagnostics, most recently as its assistant general counsel. Prior to Quest, she worked eight years at Baker-McKenzie where she was an intellectual property partner, and at Pillsbury Winthrop Shaw Pittman LLP. Ms. Wong holds a B.S. degree from the University of California-Berkeley, a Ph.D. from Florida State University-Tallahassee, and a J.D. from the University of San Diego.
Empowering patients with answers and insights for better health. View the most recent corporate presentation from Myriad Genetics.
"In 2021, during the most difficult operating environment any of us has ever seen, Myriad Genetics executed a bold transformation and growth plan that spanned virtually every part of our business."
— — Paul J. Diaz President and CEO Myriad Genetics
“For more than 31 years, Myriad Genetics has worked to be a force for good in the world as we fulfill our mission to advance health and well-being for all. In our inaugural ESG report, we seek to convey our core values as a caring, ethical, and sustainable company committed to continuous improvement,” said Paul J. Diaz, president and CEO, Myriad Genetics.